Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567314 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
A Phase 2 study of Cutaneous Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06567314 is a Phase 2 study of Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants, below the 91-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06567314, a Phase 2 study of Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06567314
The ClinicalTrials.gov registry entry for NCT06567314 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT06567314 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06567314 about?
NCT06567314 is a clinical study titled "Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma". To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
What is the current status of trial NCT06567314?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-12-02. Estimated completion is 2030-09-01.
What conditions does trial NCT06567314 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06567314?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT06567314?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06567314 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
RECRUITING · Phase 2
-
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
COMPLETED · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.